<DOC>
	<DOCNO>NCT00064389</DOCNO>
	<brief_summary>The purpose study evaluate safety levalbuterol compare racemic albuterol base frequency adverse event report 12-month period chronic dose adolescent adult subject asthma .</brief_summary>
	<brief_title>Long Term Safety Study Levalbuterol Racemic Albuterol Subjects Twelve Years Age Older With Asthma</brief_title>
	<detailed_description>This randomize , open-label , active control , multicenter , parallel-group safety study subject 12 year age old asthma . Subjects appropriate age complete Phase III levalbuterol HFA MDI trial ( Studies 051-353 051-355 ) eligible participate . Studies 051-353 051-355 , entitle `` An Efficacy Safety Study Levalbuterol , Racemic Albuterol Placebo Subjects Twelve Years Age Older Asthma '' multicenter , randomize , double-blind , placebo- active-controlled , parallel-group study nine week duration ( one-week single-blind placebo run period follow eight-week double-blind treatment period ) . Subjects complete Studies 051 353 051 355 immediately eligible rollover current study could also participate 30-day washout . New subject subject participated Phase III trial immediately eligible ( ie , &gt; 30-day washout ) consider de novo subjects.Study participation include 10 study visit 12 month period . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Inclusion Criteria Willing able comply study procedure visit schedule Females 1260 yr must negative serum pregnancy test study start Women child bear potential must use acceptable method birth control throughout study Confirmed diagnosis asthma minimum 6 mo . prior study start Have stable baseline asthma use Badrenergic agonist , and/or antiasthma antiinflammatory med , and/or OTC asthma med . &gt; 6 mo . prior study start In good health exception reversible airway disease suffer chronic condition might affect respiratory function Had chest Xray w/in 12 mo . prior randomization diagnostic pneumonia , atelectasis , pulmonary fibrotic disease , pneumothorax , chronic obstructive pulmonary disease etc . Subject roll either Sepracor study 051353 051355 must successfully complete study Subject immediately roll Sepracor study 051353 051355 must wait &gt; 30 day regard de novo subject Able complete daily diary card medical event calendar reliably , understand dose instruction , demonstrate use MiniWright PEF meter . Minor subject must parent/legal guardian assist study activity Exclusion Criteria Female pregnant lactating Participated investigational drug study w/in 30 day prior study start , currently participate another clinical trial , Sepracor study 051353 051355 Subject early terminate Sepracor study 051353 051355 Subject whose schedule prevents take first daily dose study medication and/or start study visit 10 AM Have travel commitment study would interfere trial measurement and/or compliance History hospitalization asthma w/in 45 day prior study start , schedule inpatient hospitalization , include elective surgery trial Subject know sensitivity levalbuterol racemic albuterol , excipients contain formulation Subject use prescription drug albuterol sulfate contraindicate Subject currently diagnose lifethreatening asthma History cancer ( exception : basal cell carcinoma remission ) Subject hyperthyroidism , diabetes , hypertension , cardiac disease seizure disorder currently well control medication may interfere successful completion protocol History substance abuse drug abuse within 12 month precede V1 Subject &gt; 10 pack/yr history cigarette smoking use tobacco product within 6 month study start Documented history bronchopulmonary aspergillosis form allergic alveolitis Have suffer clinically significant upper low respiratory tract infection 2 week prior study start Subject staff member relative staff member</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>